scholarly journals THE EFFECT OF L-TYPE CALCIUM CHANNELS ANTAGONISTS COMPARED TO BETA-ADRENERGIC BLOCKERS ON SPECIFIC CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CORONARY ARTERY DISEASES. A SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS OF THE PAST 20 YEARS

2019 ◽  
Vol 35 (10) ◽  
pp. S115-S116
Author(s):  
J. Roland
Keyword(s):  
Systematic Review ◽  
Coronary Artery ◽  
Calcium Channels ◽  
Meta Analysis ◽  
Cardiovascular Outcomes ◽  
Coronary Artery Diseases ◽  
Beta Adrenergic ◽  
The Past ◽  
Adrenergic Blockers

scholarly journals Coronary Artery Calcification Under Statin Therapy and Its Effect on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 7 ◽  
Author(s):  
Runmin Lai ◽  
Jianqing Ju ◽  
Qian Lin ◽  
Hao Xu
Keyword(s):  
Systematic Review ◽  
Coronary Artery ◽  
Statin Therapy ◽  
Coronary Artery Calcification ◽  
Meta Analysis ◽  
Statistical Significance ◽  
Cardiovascular Outcomes ◽  
Small Sample ◽  
The Relationship

Objective: To compare Agatston scores between patients without statin therapy and those under standard and intensive statin therapy and to systematically review the relationship between coronary artery calcification (CAC) progression under statin therapy and cardiovascular outcomes.Methods: Literature search was conducted across databases. Randomized controlled trials and observational studies that reported Agatston scores at baseline and follow-up from patients with and without statin therapy were included. A systematic review and meta-analysis was conducted.Results: Seven studies were subjected to qualitative and quantitative analyses. Agatston scores in all groups were increased at follow-up. Meta-analysis of data from the included studies revealed an insignificantly lower CAC score at follow-up in the experimental groups. Subgroup analysis showed that statins slowed down CAC progression mildly but with statistical significance in population with baseline CAC score >400 in the experimental groups (P = 0.009). Despite that calcification progressors had worse cardiovascular outcome than did non-progressors, it appeared that baseline CAC score had more decisive effects on cardiovascular outcomes. CAC progression under statin therapy did not increase cardiovascular risk, although more supportive data are needed.Conclusion: Statins do not reduce or enhance CAC as measured by Agatston score in asymptomatic populations at high risk of cardiovascular diseases, but seem to slow down CAC progression. Although our result was robust, it was restricted by small sample size and relatively short follow-up period. Further studies on the relationship between CAC progression under statin therapy and cardiovascular outcomes are needed.

Sign in / Sign up

Export Citation Format

Share Document